Literature DB >> 15710710

Improvement of stress LVEF rather than rest LVEF after coronary revascularisation in patients with ischaemic cardiomyopathy and viable myocardium.

V Rizzello1, D Poldermans, E Biagini, A F L Schinkel, R van Domburg, A Elhendy, E C Vourvouri, M Bountioukos, A Lombardo, B Krenning, J R T C Roelandt, J J Bax.   

Abstract

OBJECTIVE: To evaluate prospectively the response of left ventricular ejection fraction (LVEF) to high dose dobutamine infusion in patients showing substantial viability, with and without improved resting LVEF after revascularisation.
METHODS: Before and 9-12 months after revascularisation, 50 patients with ischaemic cardiomyopathy (LVEF 32 (8)%) and substantial myocardial viability (> or = 4 viable segments) underwent radionuclide ventriculography and dobutamine stress echocardiography. Patients were divided into group 1, patients with, and group 2, patients without significant improvement in resting LVEF (> or = 5% by radionuclide ventriculography) after revascularisation. The response of LVEF during dobutamine stress echocardiography was compared in these two groups.
RESULTS: Groups 1 and 2 were comparable in baseline characteristics, resting LVEF, and number of viable segments (mean (SD) 7 (4) v 6 (2), not significant). After revascularisation, the LVEF response during dobutamine stress echocardiography improved significantly in both groups (group 1, 34 (10)% to 56 (8)%; group 2, 32 (10)% to 46 (11)%; both p < 0.001). Interestingly, although resting LVEF did not improve in group 2, peak stress LVEF after revascularisation did (p < 0.001). Group 1 patients had, however, a greater increase in peak stress LVEF (group 1, 22 (10)%; group 2, 13 (9)%; p < 0.01). New York Heart Association and Canadian Cardiovascular Society classes decreased in both groups.
CONCLUSIONS: Although patients with viable myocardium did not always have improved rest LVEF after revascularisation, peak stress LVEF improved. Assessment of improvement of resting function may not be the ideal end point to evaluate successful revascularisation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710710      PMCID: PMC1768736          DOI: 10.1136/hrt.2004.037119

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  28 in total

1.  Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis.

Authors:  Jamieson Macdonald Bourque; Vic Hasselblad; Eric J Velazquez; Salvador Borges-Neto; Christopher M O'connor
Journal:  Am Heart J       Date:  2003-10       Impact factor: 4.749

2.  Myocardial viability: impact on left ventricular dilatation after acute myocardial infarction.

Authors:  F Nijland; O Kamp; P M J Verhorst; W G de Voogt; H G Bosch; C A Visser
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

3.  Prediction of cardiac events after uncomplicated acute myocardial infarction by clinical variables and dobutamine stress test.

Authors:  A Salustri; M Ciavatti; F Seccareccia; A Palamara
Journal:  J Am Coll Cardiol       Date:  1999-08       Impact factor: 24.094

4.  Usefulness of the ejection fraction response to dobutamine infusion in predicting functional recovery after coronary artery bypass grafting in patients with left ventricular dysfunction.

Authors:  G Rocchi; D Poldermans; J J Bax; R Rambaldi; E Boersma; A Elhendy; P van der Meer; W Vletter; J R Roelandt
Journal:  Am J Cardiol       Date:  2000-06-15       Impact factor: 2.778

5.  Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis.

Authors:  Kevin C Allman; Leslee J Shaw; Rory Hachamovitch; James E Udelson
Journal:  J Am Coll Cardiol       Date:  2002-04-03       Impact factor: 24.094

6.  Isolated annular dilation does not usually cause important functional mitral regurgitation: comparison between patients with lone atrial fibrillation and those with idiopathic or ischemic cardiomyopathy.

Authors:  Yutaka Otsuji; Toshiro Kumanohoso; Shiro Yoshifuku; Keiko Matsukida; Chihaya Koriyama; Akira Kisanuki; Shinichi Minagoe; Robert A Levine; Chuwa Tei
Journal:  J Am Coll Cardiol       Date:  2002-05-15       Impact factor: 24.094

7.  Early versus delayed revascularization in patients with ischemic cardiomyopathy and substantial viability: impact on outcome.

Authors:  Jeroen J Bax; Arend F L Schinkel; Eric Boersma; Vittoria Rizzello; Abdou Elhendy; Alexander Maat; Jos R T C Roelandt; Ernst E van der Wall; Don Poldermans
Journal:  Circulation       Date:  2003-09-09       Impact factor: 29.690

8.  Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function.

Authors:  Rob S B Beanlands; Terrence D Ruddy; Robert A deKemp; Robert M Iwanochko; Geoffrey Coates; Michael Freeman; Claude Nahmias; Paul Hendry; Robert J Burns; Andre Lamy; Lynda Mickleborough; William Kostuk; Ernest Fallen; Graham Nichol
Journal:  J Am Coll Cardiol       Date:  2002-11-20       Impact factor: 24.094

9.  Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization?

Authors:  Arend F L Schinkel; Don Poldermans; Vittoria Rizzello; Jean-Louis J Vanoverschelde; Abdou Elhendy; Eric Boersma; Jos R T C Roelandt; Jeroen J Bax
Journal:  J Thorac Cardiovasc Surg       Date:  2004-02       Impact factor: 5.209

10.  Individual prediction of functional recovery after coronary revascularization in patients with ischemic cardiomyopathy: the scar-to-biphasic model.

Authors:  Vittoria Rizzello; Arend F L Schinkel; Jeroen J Bax; Eric Boersma; Manolis Bountioukos; Eleni C Vourvouri; Boudewijn Krenning; Eustachio Agricola; Jos R T C Roelandt; Don Poldermans
Journal:  Am J Cardiol       Date:  2003-06-15       Impact factor: 2.778

View more
  1 in total

Review 1.  CSI position statement on management of heart failure in India.

Authors:  Santanu Guha; S Harikrishnan; Saumitra Ray; Rishi Sethi; S Ramakrishnan; Suvro Banerjee; V K Bahl; K C Goswami; Amal Kumar Banerjee; S Shanmugasundaram; P G Kerkar; Sandeep Seth; Rakesh Yadav; Aditya Kapoor; Ajaykumar U Mahajan; P P Mohanan; Sundeep Mishra; P K Deb; C Narasimhan; A K Pancholia; Ajay Sinha; Akshyaya Pradhan; R Alagesan; Ambuj Roy; Amit Vora; Anita Saxena; Arup Dasbiswas; B C Srinivas; B P Chattopadhyay; B P Singh; J Balachandar; K R Balakrishnan; Brian Pinto; C N Manjunath; Charan P Lanjewar; Dharmendra Jain; Dipak Sarma; G Justin Paul; Geevar A Zachariah; H K Chopra; I B Vijayalakshmi; J A Tharakan; J J Dalal; J P S Sawhney; Jayanta Saha; Johann Christopher; K K Talwar; K Sarat Chandra; K Venugopal; Kajal Ganguly; M S Hiremath; Milind Hot; Mrinal Kanti Das; Neil Bardolui; Niteen V Deshpande; O P Yadava; Prashant Bhardwaj; Pravesh Vishwakarma; Rajeeve Kumar Rajput; Rakesh Gupta; S Somasundaram; S N Routray; S S Iyengar; G Sanjay; Satyendra Tewari; Sengottuvelu G; Soumitra Kumar; Soura Mookerjee; Tiny Nair; Trinath Mishra; U C Samal; U Kaul; V K Chopra; V S Narain; Vimal Raj; Yash Lokhandwala
Journal:  Indian Heart J       Date:  2018-06-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.